oratadine and Diabetic nephropathy

Phase 3

Recruiting

• Conditions: Diabetic Nephropathy.; Type 2 diabetes mellitus with diabetic nephropathy; E11.21

• Registration Number: IRCT20201014049027N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with type 2 diabetes mellitus
Albuminuria more than 30 mg/d

Exclusion Criteria

The patients who have increased urinary protein excretion for reasons other than type 2 diabetes
eGFR less than 60 ml/min/1.73m2

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Microalbuminuria. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Urine test.